Descripción del proyecto
Avances en la terapia con linfocitos T reguladores
Las enfermedades relacionadas con el sistema inmunitario, como las enfermedades autoinmunitarias y la inflamación crónica, constituyen una importante carga socioeconómica. El tratamiento de estas enfermedades generalmente involucra medicamentos inmunosupresores, aunque se ha propuesto el empleo de linfocitos T reguladores como una terapia prometedora. El proyecto RESHAPE, financiado con fondos europeos, se propone aprovechar el papel fundamental que desempeñan los linfocitos T reguladores en la homeostasis del sistema inmunitario, ya que suprimen las respuestas inmunitarias excesivas y mantienen la tolerancia periférica. El objetivo principal es desarrollar terapias avanzadas basadas en linfocitos T reguladores y demostrar su eficacia para restaurar el equilibrio inmunitario tras la transferencia adoptiva clínica en enfermos con trastornos inmunitarios.
Objetivo
Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy.
Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments.
Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation.
Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies
Ámbito científico
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2018-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
10117 Berlin
Alemania